reports
Mauna Kea Technologies : Information relative au nombre total de droit...
PARIS--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Paris:ALMKT) : Place de cotation : Euronext Growth Paris Code ISIN : FR0010609263, Mnémonique : ALMKT Site web : Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total Brut (1) Total net (2) 30 avril 2024 61 598 117 62 637 301 62 574 815 (1) Le nombre de droits de vote bruts (ou droits de vote « théoriques ») sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l...
Pharming Group announces the early redemption of the remaining outstan...
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025 THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE IMMEDIATELY FROM THEIR STOCKBROKER, SOLICITOR, ACCOUNTANT OR OTHER INDEPENDENT FINANCIAL OR LEGAL ADVISER. THIS NOTICE IS NOT FOR DISTRIBUTION IN OR TO ANY PERSON LOCATED IN ANY JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.Leiden, the Netherlands, 15 Ma...
Mauna Kea Technologies annonce 9 présentations démontrant la valeur cl...
PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT), inventeur de Cellvizio®, la plateforme multidisciplinaire d'endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), annonce aujourd'hui qu’il y aura 9 présentations relatives au Cellvizio® à la conférence Digestive Disease Week® (DDW), qui se tiendra du 18 au 21 mai 2024 à Washington, DC. Ces abstracts portent sur l'intelligence artificielle, les lésions kystiques pancréatiques et le cancer du pancréas, l'intolérance alimentaire et d'autres troubles gastro-intestinaux. Les étu...
Mauna Kea Technologies : Mise à disposition du Rapport Financier Annue...
PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT) (Paris:ALMKT), inventeur de Cellvizio®, la plateforme multidisciplinaire d'endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des Marchés Financiers (AMF) le 30 avril 2024 son Rapport Financier Annuel relatif à l’exercice clos le 31 décembre 2023. Ce rapport peut être consulté sur le site Internet de Mauna Kea Technologies, dans les conditions prévues par la réglementation en vigueur. Il peut êtr...
Mauna Kea Technologies annonce l'ouverture d’un centre d'excellence fr...
PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT) (Paris:ALMKT) inventeur de Cellvizio®, la plateforme multidisciplinaire d'endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), annonce aujourd’hui l'ouverture d’un centre d'excellence français pour l'utilisation du Cellvizio dans le diagnostic du cancer du poumon. La procédure Cellvizio est désormais réalisée en préopératoire par le Professeur Stéphane Renaud, MD, PhD, chirurgien thoracique de référence au Centre Hospitalier Régional Universitaire (CHRU) de Nancy, France. Ce...
Mauna Kea Technologies annonce ses résultats pour l'année 2023 et son ...
PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT) inventeur de Cellvizio®, la plateforme multidisciplinaire d'endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), publie aujourd’hui ses résultats financiers pour l'année 2023 et son chiffre d'affaires pour le premier trimestre 2024. Sur l'ensemble de l'année 2023, le chiffre d'affaires total du Groupe progresse de 42% à 10,5 M€, porté par la forte croissance des volumes de l'activité PPU2 aux États-Unis et la contribution substantielle des ventes de licences. Le résultat o...
Mauna Kea Technologies conclut un accord de restructuration de son con...
PARIS & BOSTON--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Euronext Growth : ALMKT) (Paris:ALMKT), inventeur de Cellvizio®, la plateforme multidisciplinaire d'endomicroscopie confocale laser par minisonde et par aiguille (p/nCLE), annonce aujourd'hui la signature d'un accord de restructuration de 21,3 millions d'euros d'encours de dettes liés au contrat de financement avec la Banque Européenne d'Investissement (BEI). Initialement signé en juin 2019, le contrat de financement a permis à Mauna Kea d'accéder à deux tranches de prêt de 11,5 millions d'euros et 6 millions d'euro...
Pharming Group to report first quarter 2024 financial results on May 8
Pharming Group to report first quarter 2024 financial results on May 8 Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be pr...
Pharming to be honored as Industry Innovator at National Organization...
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024...
Pharming Group announces the repurchase of outstanding €125 million co...
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025 NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 19th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces the final results of its invitation to Eligible Bondholders (as defined below) of the outstanding €125 million 3.00% senior unsecured convertible bonds due 2025 issued on 21 J...
Pharming Group announces the placement of €100 million convertible bon...
Pharming Group announces the placement of €100 million convertible bonds due 2029 NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Leiden, the Netherlands, 18th April, 2024: Pharming Group N.V. ("Pharming" or the "Company") (Euronext Amsterdam: PHARM) announces today the placement of €100 million of senior unsecured convertible bonds due 2029 (the “New Bonds”) convertible into new and/or existing ordinary shares in the capital of the Company (the...
Pharming Group announces the launch of an offering of approximately €1...
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025 NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Pharming Group N.V. launches new convertible bond offering and simultaneously invites holders of its outstanding €125 million 3.00% convertible bonds due 2025 to offer their convertible bonds for purcha...
Pharming announces completion of enrollment in pediatric clinical tria...
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leiden, the Netherlands, April 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces the completion of patient enrollment in its Phase III clinical trial () evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years ...
- Baptiste Lebacq
FP TOTAL SE
AMS AMS AG
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
ENI ENI S.P.A.
REP REPSOL SA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
WAF SILTRONIC AG
XIL XILAM ANIMATION SA
MELE MELEXIS NV
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
BP. BP P.L.C.
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
WOLF SOCIETE LDC SOCIETE ANONYME
ALKAL KALRAY SA
JEN JENOPTIK AG
TMV TEAMVIEWER AG
INPST INPOST S.A.
HDF HYDROGENE DE FRANCE
SHEL SHELL PLC
FLOW FLOW TRADERS LTD
ARM ARM HOLDINGS PLC
R3NK RENK GROUP AG
- Baptiste Lebacq
- Emmanuel Matot
FP TOTAL SE
AMS AMS AG
EQNR EQUINOR ASA
GALP GALP ENERGIA SGPS SA CLASS B
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
ENI ENI S.P.A.
REP REPSOL SA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
WAF SILTRONIC AG
XIL XILAM ANIMATION SA
MELE MELEXIS NV
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
BP. BP P.L.C.
STM STMICROELECTRONICS NV
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
WOLF SOCIETE LDC SOCIETE ANONYME
ALKAL KALRAY SA
JEN JENOPTIK AG
TMV TEAMVIEWER AG
INPST INPOST S.A.
HDF HYDROGENE DE FRANCE
SHEL SHELL PLC
FLOW FLOW TRADERS LTD
ARM ARM HOLDINGS PLC
R3NK RENK GROUP AG
- Fatma Agnès Hamdani
LDC : Q4 broadly in line. Volume recovery for the poultry France divis...
>Organic decline in Q4 sales of 1.5% vs -0.3%e due to more negative price effects. Volumes in the poultry France division recovered by +5.5% - LDC yesterday evening reported Q4 2023-24 sales close to our expectations. Sales were up a slight 1.6% to € 1,645.4m (vs cons. € 1,648m and ODDO BHF € 1,653m est.). Organic growth was a bit weaker at -1.5% versus -0.3% expected, reflecting bigger price decreases in poultry. Q4 sales in the poultry France division excluding...
- Fatma Agnès Hamdani
LDC : Un T4 globalement en ligne. Redressement des volumes pour le pôl...
>Décroissance organique du CA T4 de 1.5% vs -0.3%e en raison des effet prix plus négatifs. Les volumes se redressent pour le pôle volaille France de +5.5% - LDC a publié hier soir un CA T4 2023/24 proche de nos attentes. Les ventes ressortent en légère hausse de 1.6% à 1645.4 M€ (vs cons. 1648 M€ et 1653 M€e). La croissance organique est un peu plus faible à -1.5% contre -0.3% attendus, reflétant une baisse des prix plus élevée en volaille. Le CA T4 du pôle Volai...
Mauna Kea Technologies : Information relative au nombre total de droit...
PARIS--(BUSINESS WIRE)-- Regulatory News: Mauna Kea Technologies (Paris:ALMKT) : Place de cotation : Euronext Growth Paris Code ISIN : FR0010609263, Mnémonique : ALMKT Site web : Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total Brut (1) Total net (2) 31 mars 2024 61 598 117 62 633 559 62 577 561 (1) Le nombre de droits de vote bruts (ou droits de vote « théoriques ») sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l’...
Pharming Group announces the 2024 Annual General Meeting of Shareholde...
Pharming Group announces the 2024 Annual General Meeting of Shareholders Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2024 Annual General Meeting of Shareholders (the “AGM”) will be held on Tuesday, May 21, 2024 at 14:30 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The agenda of the AGM includes the reappointment of Ms. Barbara Yanni and Mr. Mark Pyk...
Pharming Group announces the filing of its 2023 Annual Report and Form...
Pharming Group announces the filing of its 2023 Annual Report and Form 20-F Leiden, The Netherlands, April 4, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2023 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2023 Annual Report on Form 20-F can be found unde...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.